8-K: Pulse Biosciences Appoints Paul LaViolette as CEO, Bolsters Leadership Team

Paul LaViolette, current Co-Chairman of the Board, has been appointed as the new CEO of Pulse Biosciences, effective January 9, 2025, alongside the grant of inducement awards to new employees.

Summary

• Pulse Biosciences has appointed Paul LaViolette, previously Co-Chairman of the Board, as its new Chief Executive Officer, effective January 9, 2025.
• LaViolette's employment agreement includes an annual base salary of $725,000 and eligibility for an annual target bonus of up to 70% of his base salary, contingent on achieving performance objectives set by the company.
• He has also been granted stock options to purchase 1,500,000 shares of the company's common stock at an exercise price of $18.43 per share.
• The options vest over time, with portions tied to market capitalization and revenue milestones, including achieving a market cap between $3 billion and $9 billion and revenue targets ranging from $48 million to $500 million.
• Eleven other new employees received inducement awards of options to purchase a total of 138,800 shares of common stock.
• These options have an exercise price of $18.55 per share and generally vest over four years, with a portion of a vice president's grant tied to market capitalization milestones.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the appointment of an experienced CEO, the granting of stock options to align interests, and the ongoing development of innovative technology. The ambitious performance targets suggest confidence in the company's future prospects.

Positives

• The appointment of Paul LaViolette brings significant experience from large healthcare corporations and medical technology startups to Pulse Biosciences.
• LaViolette's track record includes scaling global franchises and driving the adoption of innovative technologies.
• The inducement grants to new employees demonstrate the company's commitment to attracting and retaining talent.
• The performance-based vesting of LaViolette's stock options aligns his interests with the long-term success of the company and achieving ambitious financial goals.

Risks

• The vesting of a significant portion of LaViolette's stock options is contingent on achieving ambitious market capitalization and revenue targets, which may not be realized.
• The company's success depends on the continued development and commercialization of its nano-PFA technology.
• The at-will employment agreement allows for termination at any time, which could create uncertainty.

Future Outlook

Pulse Biosciences is continuing the development of its nano-PFA Cardiac Surgical System and nano-PFA 360 Cardiac Catheter through first-in-human feasibility studies in Europe and is conducting a pilot program with its FDA-cleared nsPFA Percutaneous Electrode Systems at select sites in the United States.

Management Comments

• Robert W. Duggan, Co-Chairman of the Board, stated that he and LaViolette have a strong working relationship and aligned visions for the future of Pulse.
• Paul LaViolette believes nano-PFA is a remarkable advance in medical technology and will make a profound impact on healthcare.

Industry Context

The appointment of a seasoned executive like Paul LaViolette signals Pulse Biosciences' commitment to scaling its operations and commercializing its nano-PFA technology in the competitive bioelectric medicine market.

Comparison to Industry Standards

• Paul LaViolette's previous roles at Boston Scientific and Edwards Lifesciences provide him with experience comparable to leaders at other major medical device companies.
• The performance-based vesting of stock options is a common practice in the industry to align executive compensation with company performance, similar to incentive plans at companies like Medtronic and Abbott.
• The market capitalization and revenue targets for vesting are ambitious but reflect the potential of Pulse Biosciences' technology in the growing field of pulsed field ablation.

Management Changes

Stakeholder Impact

• Shareholders: The appointment of a new CEO and the development of nano-PFA technology could positively impact the company's stock price and long-term value.
• Employees: The inducement grants to new employees demonstrate the company's commitment to attracting and retaining talent, potentially improving morale and productivity.
• Patients: The development of nano-PFA technology has the potential to improve the quality of life for patients suffering from atrial fibrillation and other conditions.
• Providers: The nano-PFA technology could offer providers a new and effective treatment option for various medical conditions.

Next Steps

• Continued development and clinical trials of the nano-PFA Cardiac Surgical System and nano-PFA 360 Cardiac Catheter.
• First-in-human feasibility studies in Europe.
• Pilot program with FDA-cleared nsPFA Percutaneous Electrode Systems at select sites in the United States.
• Presentation at the J.P. Morgan Healthcare Conference on January 15, 2025.
• Participation in the AF Symposium 2025 meeting from January 16-18, 2025.

Key Dates